A three month course of low-dose azithromycin may protect people hospitalised with a severe acute exacerbation of COPD from recurrent attacks, a European trial suggests. The macrolide antibiotic may offer a targeted prevention approach for COPD patients by reducing treatment failure and rehospitalisation in the high-risk period following an acute severe exacerbation, according to Belgian ...
COPD
Low dose azithromycin may reduce treatment failure after COPD exacerbation
By Michael Woodhead
28 May 2019